4 December 2019

OFFICIAL NAME CHANGE TO ZELIRA THERAPEUTICS

Following approval by Shareholders at the Annual General Meeting on 28 November 2019 and confirmation from ASIC effecting the name change, Zelda Therapeutics Limited (ASX:ZLD) today confirms it has changed its name to **Zelira Therapeutics Limited** effective, 5 December 2019.

The Company's ASX code will remain **ZLD.**

Tim Slate
Company Secretary

About Zelira Therapeutics (www.zeliratherapeutics.com)

Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking:

- **Human clinical trial programs** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- **Pre-clinical research** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The Company conducts this work in partnership with world-leading researchers and organizations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelira has also formed a strategic partnership with European medicinal cannabis group HAPA Pharm BV, to access HAPA Pharm's EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialization for successful clinically validated formulations.

The Company has developed two proprietary formulations (HOPE®) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products. The company also has a partnership with Ethicann for the development of a proprietary product, CAN-001, which is being developed for the treatment of chemotherapy-induced nausea and vomiting (CINV), which occurs in approximately 80% of the new 23.6 million cases of cancer annually worldwide.

###

Address
Level 26
140 St Georges Terrace, Perth WA 6000 AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeliratherapeutics.com
ACN 103 782 378

Tickers
Australia (ASX): ZLD USA
(OTCQB): ZLDAF

Australia Contact
Dr Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeldatherapeutics.com

Monsoon Communications
Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

U.S. Contacts:
Dr. Oludare Odumosu
Managing Director & CEO, USA
+1-909-855-0675
oodumosu@zeliratx.com
3553 West Chester Pike #110,
Newtown Square, PA 19073

GVM Communications, Inc.
Gia Morón,
347-678-8079 |
gia@gvmcommsinc.com